Tempus Ai,Inc.(TEM) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for the core business increased by over 33% in 2025, with the acquisition of Ambry contributing to even higher growth [5] - Net revenue retention was reported at 126%, indicating strong customer loyalty and increased spending [7] - The company guided for $1.59 billion in revenue for 2026, aligning with long-term growth expectations of approximately 25% [7] Business Line Data and Key Metrics Changes - In the diagnostics segment, oncology unit growth reached 29%, with a remarkable 56% quarter-over-quarter growth in minimal residual disease (MRD) testing [5][36] - The hereditary testing segment maintained a solid 23% unit growth [5] - The data business, particularly the licensing segment, saw a 69% increase in the quarter, with projections of around 40% growth for the upcoming quarter [6] Market Data and Key Metrics Changes - The company has established connections with over 5,500 hospitals and more than 8,500 oncologists, enhancing its market presence [12] - The total contract value for the data business exceeded $1.1 billion, indicating robust demand and growth potential [6] Company Strategy and Development Direction - The company aims to leverage its unique data advantages and AI capabilities to enhance diagnostic offerings and maintain a competitive edge in the healthcare sector [11][12] - The strategic focus includes expanding the comprehensive nature of its testing portfolio, particularly through the integration of hereditary and oncology testing [61] - The company plans to continue investing in technology and AI to drive growth and improve diagnostic accuracy [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, citing strong demand for data products and a solid foundation for revenue growth [49] - The company anticipates continued strong performance in oncology diagnostics, with expectations of high teens growth in hereditary testing [30][56] - Management highlighted the importance of proprietary data in training AI models, which is expected to enhance the company's offerings and market position [11][12] Other Important Information - The company is in the process of developing a foundation model for AI, with expectations of significant advancements in diagnostic capabilities [28] - The average selling price (ASP) for tests was reported at approximately $1,640, with potential for significant increases in the coming years [22] Q&A Session Summary Question: Concerns about AI and market competition - Management emphasized the unique position of the company due to its proprietary data and established relationships with healthcare providers, which are difficult for competitors to replicate [11][12] Question: Strategic value of Paige Predict and its impact - Management discussed the importance of contextualizing diagnostics and how new technologies like Paige Predict enhance the value of their offerings [17][19] Question: Update on foundation model development - Management confirmed that benchmarks for the foundation model have been met and that testing is ongoing, with expectations for significant value delivery [28] Question: Volume growth assumptions for 2026 - Management indicated that oncology growth is off to a strong start, with expectations of continued growth, while hereditary testing may see some moderation [30][56] Question: Insights on MRD testing and sales force effectiveness - Management highlighted the strong performance of MRD testing despite a constrained sales effort, indicating potential for significant growth once fully deployed [36][37] Question: ASP outlook and gross margin implications - Management noted that increases in ASP would likely lead to improved gross margins, while balancing the need for comprehensive testing panels [78]